Publication:


abstract

Malignant Melanoma is characterized by a rapid progression, metastasis to distant organs, and resistance to chemo- and radiotherapy. Well-defined immunogenic capacities of melanoma cells should allow a successful application of different immunotherapeutic strategies. However, the overall results of immunotherapeutic clinical studies are not satisfactory. These paradoxical observations are supposed to be due to the profound immunosuppression mediated by different mechanisms dealing with alterations in tumor and surrounding stroma cells. Melanoma microenvironment has been characterized by a remarkable accumulation of highly immunosuppressive regulatory leucocytes, in particular, myeloid-derived suppressor cells (MDSCs). Their migration, retention and high activity in the tumor lesions have been demonstrated to be induced by chronic inflammatory conditions developing in the tumor microenvironment and characterized by the long-term secretion of various inflammatory mediators (cytokines, chemokines, growth factors, reactive oxygen and nitrogen species, prostaglandins etc.) leading to further cancer progression. Here, we discuss the role of chronic inflammation in the recruitment and activation of MDSCs in melanoma lesions as well as therapeutic approaches of MDSC targeting to overcome tumor immunosuppressive microenvironment induced by chronic inflammation and enhance the efficiency of melanoma immunotherapies.

Copyright © 2012 Elsevier Ltd. All rights reserved.

Related Articles
Overcoming immunosuppression in the melanoma microenvironment induced by chronic inflammation.
Cancer Immunol Immunother. 2012
Overcoming immunosuppression in the melanoma microenvironment induced by chronic inflammation.
Umansky V, Sevko A. Cancer Immunol Immunother. 2012 Feb; 61(2):275-82. Epub 2011 Nov 27.
Review Immunosuppressive cells and tumour microenvironment: focus on mesenchymal stem cells and myeloid derived suppressor cells.
Histol Histopathol. 2011
Review Immunosuppressive cells and tumour microenvironment: focus on mesenchymal stem cells and myeloid derived suppressor cells.
Bianchi G, Borgonovo G, Pistoia V, Raffaghello L. Histol Histopathol. 2011 Jul; 26(7):941-51.
Serum inhibits the immunosuppressive function of myeloid-derived suppressor cells isolated from 4T1 tumor-bearing mice.
Cancer Immunol Immunother. 2012
Serum inhibits the immunosuppressive function of myeloid-derived suppressor cells isolated from 4T1 tumor-bearing mice.
Hamilton MJ, Banáth JP, Lam V, Lepard NE, Krystal G, Bennewith KL. Cancer Immunol Immunother. 2012 May; 61(5):643-54. Epub 2011 Oct 22.
Review Molecular insights into prostate cancer progression: the missing link of tumor microenvironment.
J Urol. 2005
Review Molecular insights into prostate cancer progression: the missing link of tumor microenvironment.
Chung LW, Baseman A, Assikis V, Zhau HE. J Urol. 2005 Jan; 173(1):10-20.
Review Inflammation: gearing the journey to cancer.
Mutat Res. 2008
Review Inflammation: gearing the journey to cancer.
Kundu JK, Surh YJ. Mutat Res. 2008 Jul-Aug; 659(1-2):15-30. Epub 2008 Mar 16.